4-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzonitrile | 945393-48-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 4-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzonitrile
• 英文别名: 4-[[4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl]amino]benzonitrile
• CAS: 945393-48-6
• 化学式: C₁₈H₁₂ClN₅O₂
• 分子量: 365.779
• InChiKey: VPEQURIWBMCLKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  92.1
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-chloro-N-(5-chlorobenzo[d][1,3]dioxol-4-yl)pyrimidin-4-amine 、 对氨基苯腈 在 盐酸 作用下， 生成 4-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzonitrile
  参考文献：
  名称：

  Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines

  摘要：

  A series of bis-anilinopyrimidines have been identified as potent inhibitors of the tyrosine kinase EphB4. Structural information from two alternative series identified from screening efforts was combined to identify the initial leads.

  DOI：

  10.1016/j.bmcl.2008.04.015

文献信息

• PYRIMIDINE DERIVATIVES
  申请人：Kettle Jason Grant

  公开号：US20110046108A1

  公开（公告）日：2011-02-24

  The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R 1 , ring A, n, R 3 , and R 4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.

  这项发明涉及Formula (I)的苯甲酰胺化合物或其药用可接受的盐，其中R1、环A、n、R3和R4如描述中所定义。本发明还涉及制备这种化合物的方法、含有它们的药物组合物以及它们在制造用作抗增殖剂的药物中的用途，用于预防或治疗对EphB4、EphA2和/或Src激酶抑制敏感的肿瘤或其他增殖病症。
• [EN] PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRIMIDINE
  申请人：ASTRAZENECA AB

  公开号：WO2007085833A2

  公开（公告）日：2007-08-02

  [EN] The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R¹, ring A, n, R³, and R⁴ are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.
  [FR] La présente invention concerne des composés de benzamide de Formule (I) ou un sel dérivé pharmaceutiquement acceptable, où R¹, le cycle A, n, R³, et R⁴ sont tels qu'énoncés dans la description. La présente invention a aussi trait à des processus de préparation de tels composés, à des compositions pharmaceutiques les contenant et à leur utilisation dans la fabrication d'un médicament à utiliser comme agent antiproliférateur pour la prévention ou le traitement de tumeurs ou d'autres conditions prolifératrices qui sont sensibles à l'inhibition des kinases EphB4, et/ou EphA2 et/ou Src.
• Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines
  作者：Catherine Bardelle、Darren Cross、Sara Davenport、Jason G. Kettle、Eun Jung Ko、Andrew G. Leach、Andrew Mortlock、Jon Read、Nicola J. Roberts、Peter Robins、Emma J. Williams

  DOI：10.1016/j.bmcl.2008.04.015

  日期：2008.5

  A series of bis-anilinopyrimidines have been identified as potent inhibitors of the tyrosine kinase EphB4. Structural information from two alternative series identified from screening efforts was combined to identify the initial leads.